Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 602 participants.
Also called NCT07630454
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 602 participants
- Sponsor
- Registry
-
NCT07630454
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07630454. Randomized; single masking; primary purpose prevention. Start 2026-08-01 (anticipated); primary completion 2029-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
- Acronym
- TEAR-AF-HFpEF
- Condition
- Atrial Fibrillation
- Condition
- Tirzepatide
- Intervention (Drug)
- Tirzepatide
- Intervention (Behavioral)
- Structured Lifestyle Intervention
- Lead sponsor
- Yunlong Wang
- Collaborator
- Shanghai Zhongshan Hospital
Record details
- Record id
cardio:ct-nct07630454- Content hash
620b4704782f1fc902871ec3d161ddb0f1eb022e9bea7a49a7fedfb2462df738